

Filed: August 20, 2026

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PFIZER INC.,
Petitioner,

v.

POGONA, LLC,
Patent Owner.

Case IPR2026-00189
Patent 11,058,757

PATENT OWNER'S UPDATED EXHIBIT LIST

Patent Owner Pogona, LLC hereby submits its updated exhibit list:

Exhibit No.	Description
2001	Declaration of Bruce D. Forrest in Support of Patent Owner's Discretionary Denial Brief, dated March 5, 2026
2002	<i>Liffey/Vax Executive Summary: Expanded Coverage Twenty-Valent Pneumococcal Conjugate Vaccine (ePCV20) Executive Summary</i> , Liffey Biotech Ltd., July 8, 2018
2003	Confidential Disclosure Agreement between Liffey Biotech Ltd. and Pfizer Inc., dated March 25, 2019
2004	International Patent Publication No. WO 2020/121159 A1 (PCT/IB2019/106562) titled "Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and Uses Thereof," published June 18, 2020
2005	Google Patents U.S. Patent No. 11,058,757
2006	Court's Order (Dkt. 33), <i>Pogona, LLC v. Merck Sharp & Dohme LLC</i> , No. 2:25-cv-15294-BRM-JBC (D.N.J.), dated March 2, 2026
2007	Matanock, M.D., Almea, et al., <i>Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices</i> , Morbidity and Mortality Weekly Report, Vol. 68 No. 46 (2019)
2008	Cynthia Whitney, M.D., MPH, <i>Pneumococcal Vaccines for Older Adults: What is the right approach?</i>
2009	Almea Matanock, M.D., <i>Invasive Pneumococcal Disease in the U.S. – 2008-2016</i> , National Center for Immunization & Respiratory Diseases, October 26, 2017
2010	Decision on Appeal, <i>Ex parte Smith</i> , No. 2011-003337 (PTAB Feb. 28, 2012)
2011	Judgment, <i>Ex parte Smith</i> , No. 2012-001344 (Fed. Cir. Nov. 20, 2012)

Exhibit No.	Description
2012	Decision on Appeal, <i>Ex Parte Eckhardt</i> , No. 2020-003463 (PTAB Apr. 15, 2021)
2013	Appellant's Appeal Brief, <i>Ex Parte Eckhardt</i> , No. 71049US008 (filed Nov. 4, 2019)
2014	Plaintiff-Appellant's [Corrected] Brief, <i>3Form, Inc. v. Lumicor, Inc.</i> , No. 2016-001535 (Fed. Cir. May 10, 2016)
2015	Santiesteban-Lores, et al., <i>Development of a pneumococcal conjugate vaccine based on chemical conjugation of polysaccharide serotype 6B to PspA</i> , <i>Microbial Pathogenesis</i> 158 (2021)
2016	Declaration of Ali Fattom, Ph.D., dated Sept. 2017, submitted in <i>Merck Sharp & Dohme Corp. v. Wyeth LLC</i> , No. IPR2017-00390
2017	Declaration of Sarah E. Spires in Support of Patent Owner's Supplemental Evidence in Response to the Objections to Preliminary Evidence filed by Petitioner
2018	Declaration of Dr. George G. Zhanel, Ph.D. in Support of Patent Owner's Response
2019	Curriculum Vitae of Dr. George G. Zhanel, Ph.D.
2020	Declaration of Dr. Louis J. Defilippi, Ph.D. in Support of Patent Owner's Response
2021	Curriculum Vitae of Dr. Louis J. DeFilippi, Ph.D.
2022	Deposition Transcript of Luwy K. Musey, M.D., taken July 23, 2026
2023	Feikin et al., <i>Serotype-Specific Changes in Invasive Pneumococcal Disease after Pneumococcal Conjugate Vaccine Introduction: A Pooled Analysis of Multiple Surveillance Sites</i> , <i>PLOS Medicine</i> (2013)
2024	Supporting Information for Feikin et al., <i>Serotype-Specific Changes in Invasive Pneumococcal Disease after Pneumococcal Conjugate Vaccine Introduction: A Pooled Analysis of Multiple Surveillance Sites</i> , <i>PLOS Medicine</i> (2013)

Exhibit No.	Description
2025	Imöhl et al., <i>Pneumococcal Meningitis and Vaccine Effects in the Era of Conjugate Vaccination: Results of 20 Years of Nationwide Surveillance in Germany</i> , BMC Infectious Diseases (2015)
2026	Chiang et al., <i>National Surveillance of Invasive Pneumococcal Diseases in Taiwan, 2008–2012: Differential Temporal Emergence of Serotype 19A</i> , Vaccine 32 (2014)
2027	OlarTE et al., <i>Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis in US Children</i> , Clinical Infectious Diseases (2015)
2028	Jin et al., <i>Using a Practical Molecular Capsular Serotype Prediction Strategy to Investigate Streptococcus pneumoniae Serotype Distribution and Antimicrobial Resistance in Chinese Local Hospitalized Children</i> , BMC Pediatrics (2016)
2029	Steens et al., <i>A Review of the Evidence to Inform Pneumococcal Vaccine Recommendations for Risk Groups Aged 2 Years and Older</i> , Epidemiol. Infect. (2014)
2030	Centers for Disease Control & Prevention, <i>Updated Recommendations for Prevention of Invasive Pneumococcal Disease Among Adults Using the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23)</i> , Morbidity and Mortality Weekly Report (2010)
2031	Tomczyk et al., <i>Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥ 65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP)</i> , Morbidity and Mortality Weekly Report (2014)
2032	Marsh et al., <i>Molecular Characterisation of Pneumococcal Serotype 16F: Established Predominant Carriage and Otitis Media Serotype in the 7vPCV Era</i> , Vaccine 25 (2007)

Exhibit No.	Description
2033	Andrews et al., <i>Serotype-Specific Effectiveness and Correlates of Protection for the 13-Valent Pneumococcal Conjugate Vaccine: A Postlicensure Indirect Cohort Study</i> , Lancet Infectious Diseases (2014)
2034	Rajam et al., <i>Functional Antibodies to the O-Acetylated Pneumococcal Serotype 15B Capsular Polysaccharide Have Low Cross-Reactivities with Serotype 15C</i> , Clinical and Vaccine Immunology (Sept. 2007)
2035	H. Findlow & R. Borrow, <i>Interactions of Conjugate Vaccines and Co-Administered Vaccines</i> , Human Vaccines & Immunotherapeutics (2016)
2036	Park et al., <i>Discovery of a New Capsular Serotype (6C) within Serogroup 6 of Streptococcus pneumoniae</i> , Journal of Clinical Microbiology (2007)
2037	Cooper et al., <i>The 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Elicits Cross-Functional Opsonophagocytic Killing Responses in Humans to Streptococcus pneumoniae Serotypes 6C and 7A</i> , Vaccine 29 (2011)
2038	Metcalf et al., <i>Strain Features and Distributions in Pneumococci from Children with Invasive Disease Before and After 13-Valent Conjugate Vaccine Implementation in the USA</i> , Clinical Microbiology and Infection (2016)
2039	Diao et al., <i>Efficacy of 23-Valent Pneumococcal Polysaccharide Vaccine in Preventing Community-Acquired Pneumonia Among Immunocompetent Adults: A Systematic Review and Meta-Analysis of Randomized Trials</i> , Vaccine 34 (2016)
2040	Lamontagne et al., <i>Pneumococcal Vaccination and Risk of Myocardial Infarction</i> , Canadian Medical Association Journal (2008)

Exhibit No.	Description
2041	Vila-Corcoles et al., <i>Clinical Effectiveness of Pneumococcal Vaccination Against Acute Myocardial Infarction and Stroke in People Over 60 Years: The CAPAMIS Study, One-Year Follow-Up</i> , BMC Public Health (2012)
2042	Choi et al., <i>Capsular Polysaccharide (CPS) Release by Serotype 3 Pneumococcal Strains Reduces the Protective Effect of Anti-Type 3 CPS Antibodies</i> , Clinical and Vaccine Immunology (2016)
2043	Pichichero et al., <i>Next Generation Protein Based Streptococcus pneumoniae Vaccines</i> , Human Vaccines & Immunotherapeutics (2016)
2044	Feldman & Anderson, <i>Review: Current and New Generation Pneumococcal Vaccines</i> , Journal of Infection (2014)
2045	Jason W. Rosch, <i>Promises and Pitfalls of Live Attenuated Pneumococcal Vaccines</i> , Human Vaccines & Immunotherapeutics (2014)
2046	Leroux-Roels et al., <i>Safety, Reactogenicity and Immunogenicity of a Novel Pneumococcal Protein-Based Vaccine in Adults: A Phase I/II Randomized Clinical Study</i> , Vaccine 32 (2014)
2047	Rudolph et al., <i>Epidemiology of Pneumococcal Serotype 6A and 6C Among Invasive and Carriage Isolates from Alaska, 1986–2009</i> , Diagnostic Microbiology and Infectious Disease (2013)
2048	Jessie A. Key, <i>Factors that Affect the Rate of Reactions</i> , Introductory Chemistry – 1st Canadian Edition (2014)
2049	<i>Classification of Variables in Chemical Process Control</i> (CHEMICAL ADDA, Feb. 22, 2016)
2050	Declaration of Sarah E. Spires in Support of Patent Owner’s Supplemental Evidence in Response to Petitioner Pfizer Inc.’s Objections to Patent Owner’s Evidence

Dated: August 20, 2026

Respectfully submitted,

/Sarah E. Spires/

Counsel for Patent Owner

Reg. No. 61,501

SKIERMONT DERBY LLP

1601 Elm Street, Suite 4400

Dallas, Texas 75201

P: 214-978-6600/F: 214-978-6601

CERTIFICATE OF SERVICE

The undersigned hereby certifies that a true and correct copy of the foregoing **PATENT OWNER'S UPDATED EXHIBIT LIST** was served on August 20, 2026, by delivering a copy via electronic mail to the attorneys of record for Petitioner as follows:

David Krinsky (Reg. No. 72,339)

dkrinsky@wc.com

Julie Tavares (Reg. No. 77,398)

jtavares@wc.com

Yujung Rho (*pro hac vice* requested)

yrho@wc.com

WILLIAMS & CONNOLLY LLP

Dated: August 20, 2026

/Sarah E. Spires/

Sarah E. Spires (Reg. No. 61,501)

Counsel for Patent Owner